Setting Our Sights On 2008
Alan B. Guralnick, Publisher
Genentech to Halt Avastin Sales to Compounding Pharmacies
The company said it continues to actively listen to physicians' concerns and will try to address them in a productive fashion.
Conni Bergmann Koury, Editor-in-Chief and Leah D. Farr, Associate Editor
Early Detection of AMD Is Crucial to Preserve Vision
Even with better treatment options, early detection is key to preserving vision and maintaining quality of life.
Anat Loewenstein, MD
Vitreoretinal Surgeons Pick up Endoscopes
The endoscope has become a key tool in modern microincisional and minimally invasive diagnostic and therapeutic modalities.
Christopher D. Riemann, MD
OCT After Intravitreal Anti-VEGF Therapies for AMD
A quantitative comparison of intravitreal ranibizumab, bevacizumab, and pegaptanib.
SriniVas R. Sadda, MD, Christopher D. Riemann, MD
Intravitreal Dexamethasone as an Adjunct in the Treatment of Neovascular AMD
Our preliminary work suggests that intravitreal dexamethasone may be a safe adjunctive treatment when used in combination with PDT and anti-VEGF agents.
Subhransu Ray, MD, PhD
NEI VFQ-25 Useful Tool for Determining Patients' Vision-Related Function
The NEI VFQ-25 measures the dimensions of self-reported vision-targeted health status that are most important for individuals who have chronic eye diseases.
Gregg T. Kokame, MD, MMM
Positive Primary Endpoint Results Reported in Phase 2 VEGF Trap-Eye
Retinal thickness was reduced, and vision was improved in patients with neovascular AMD.
Jeffrey S. Heier, MD
Higher-Dose VEGF Trap-Eye May Enhance Results in Neovascular AMD
Intravitreal injection of up to 4 mg of VEGF Trap-Eye was well tolerated, and no evidence of ocular inflammation was detected.
Quan Dong Nguyen, MD, MSc
Detection of Subclinical Exudative AMD With a Clinical Challenge Test
Patients' visual acuity will be better the earlier they can receive treatment.
Tongalp H. Tezel, MD
Asymptomatic Patients With Increased ART May Have Underlying Occlusive Disease
The average ART is 12 to 15 seconds. There are numerous potential causes for ART delay, including myocardial and pulmonary disease.
Joseph I. Maguire, MD; Richard Scartozzi, MD; and Robert C. Sergott, MD
Adult Retinal Stem Cell Spheres Hold Potential for DR Treatment
RSC sphere cells may prevent or slow down the vascular damage and neovascularization in diabetic retinopathy, as well as provide new retinal cells to replenish those retinal neurons lost to disease.
Beatrix Kovacs, PhD, Mathew W. MacCumber, MD, PhD, and Shunbin Xu, MD, PhD
Quality of Life and Treatment of AMD
Jointly sponsored by The Dulaney Foundation and Retina Today. Release Date: November 1, 2007. Expiration Date: December, 31, 2008. This continuing medical education activity is supported by an educational grant from Genentech.
Tom S. Chang, MD
In Tribute: Charles L. Schepens, MD
The 40th Annual Retina Society Scientific Meeting, held this year in Boston, honored the late Charles L. Schepens, MD, long considered a leader in retinal detachment surgery. In this issue, Retina Today has dedicated this page to Dr. Schepens, a pioneering ophthalmologist.